Investigational drug · Phase 3
JMT103
Also called: Narlumosbart
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Giant Cell Tumor of Bone, Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "JMT103"
First trial start
2023
Apr 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JMT103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Giant Cell Tumor of Bone
- Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JMT103" as an intervention, largest first.
- A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic AcidPivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT06221072 · 1,360 participants (planned) · Start Apr 5, 2024 · Primary completion May 31, 2027
Drug: JMT103; zoledronic acid · For: Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
- Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone DiseasePivotal-lookingNot yet recruiting
RenJi HospitalAcademic, hospital or other
NCT06314698 · 478 participants (planned) · Start Apr 1, 2024 · Primary completion Dec 31, 2024
Drug: Narlumosbart; Denosumab · For: Multiple Myeloma; Bone Diseases
- Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid TumorsPivotal-lookingCompleted
Shanghai JMT-Bio Inc.Industry
NCT04630522 · 295 participants · Start Oct 31, 2020 · Primary completion Mar 31, 2023
Drug: Drug: JMT103- 120 mg SC Q4W; Drug: JMT103- 120 mg SC Q8W and 1 more · For: Bone Metastases From Solid Tumors
Sites: Shanghai, China
- Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced OsteoporosisPivotal-lookingStatus unknown
Shanghai JMT-Bio Inc.Industry
NCT05397938 · 231 participants (planned) · Start Jun 15, 2022 · Primary completion Jul 1, 2022
Drug: JMT103; Alendronate sodium and 2 more · For: Glucocorticoid Induced Osteoporosis
Sites: Beijing, China
- Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With OsteoporosisPivotal-lookingStatus unknown
Shanghai JMT-Bio Inc.Industry
NCT05278338 · 200 participants (planned) · Start Apr 21, 2022 · Primary completion Dec 31, 2023
Drug: JMT103; Denosumab and 1 more · For: Postmenopausal Osteoporosis
Sites: Changchun, China
- A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of BonePivotal-lookingNot yet recruiting
Shanghai JMT-Bio Inc.Industry
NCT05813665 · 146 participants (planned) · Start Apr 2023 · Primary completion Jun 2028
Drug: Narlumosbart; Denosumab · For: Giant Cell Tumor of Bone
Sites: Beijing, China
Shanghai JMT-Bio Inc.Industry
NCT03550508 · 36 participants (planned) · Start May 21, 2018 · Primary completion Aug 30, 2019
Drug: Anti-RANKL Monoclonal Antibody · For: Bone Metastases
Sites: Shanghai, China
- A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCMTerminated
Shanghai JMT-Bio Inc.Industry
NCT04198480 · 4 participants · Start Apr 22, 2020 · Primary completion Oct 25, 2021
Drug: JMT103 · For: Hypercalcemia of Malignancy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol.
Li J, Zhou N, Lu S, et al. · BMJ Open 2026
- Curcumin nanoparticles combined with narlumosbart regulate wingless-type MMTV integration site (wnt)/β-catenin signaling pathway in osteoblast-like cells.
Zhang H, Zhao Y · Pak J Pharm Sci 2026
- JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison.
Xu H, Zhou Y, Wei F, et al. · Cancer Med 2025
- Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.
Chi Y, Li Y, Cheng Q, et al. · EClinicalMedicine 2025
- Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.
Ran R, Li H, Sun T, et al. · Int J Cancer 2025
- Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.
Xu H, Zhou Y, Liang L, et al. · Nat Commun 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.